<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802915</url>
  </required_header>
  <id_info>
    <org_study_id>124575</org_study_id>
    <nct_id>NCT04802915</nct_id>
  </id_info>
  <brief_title>Intraoperative Analysis of the Central Retina in ERF</brief_title>
  <official_title>Intraoperative Analysis of the Central Retina in Epiretinal Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The S.N. Fyodorov Eye Microsurgery State Institution</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Makarenko Irina Romanovna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zgoba Mariana Igorevna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The S.N. Fyodorov Eye Microsurgery State Institution</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Changes in the retinal anatomy that occur in epiretinal fibrosis have not been sufficiently&#xD;
      studied. It is possible that epiretinal fibrosis leads not only to traction dislocation of&#xD;
      the macula, but also to ILM anatomical disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: to study anatomical changes in the Central retina in epiretinal fibrosis.&#xD;
&#xD;
      Surgical treatment: standard vitrectomy 25-27G; ERM amd ILM stainig by Membrane Blue Dual;&#xD;
      epiretinal membrane removal, ILM peeling if the divulsion of ILM was detected.&#xD;
&#xD;
      Expected results: improving the quality of epiretinal fibrosis surgery by obtaining a more&#xD;
      detailed picture of the pathological process&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ILM integrity</measure>
    <time_frame>intraoperative</time_frame>
    <description>Visual intraoperative assessment of the ILM integrity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length and localization of the ILM dialysis</measure>
    <time_frame>intraoperative</time_frame>
    <description>Length (in degrees) and localization of the ILM dyalisis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ILM displacement</measure>
    <time_frame>intraoperative</time_frame>
    <description>ILM displacement direction during the formation of detachment and divulsion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurence of ILM dyalisis</measure>
    <time_frame>intraoperative</time_frame>
    <description>Determination of the ratio of patients with ILM dialysis to the total number of patients with ERF</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Epiretinal Membrane</condition>
  <condition>Macular Pucker</condition>
  <arm_group>
    <arm_group_label>epiretinal membrane group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with epiretinal fibrosis confirmed by OCT with BCVA&lt; 0,6 and complaints of metamorphopsies</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intraoperative ERM and ILM staining with their assessment and removal</intervention_name>
    <description>ERM and ILM staining is performed after vitrectomy. After that we evaluate the condition of macular zone and make a decision to remove the ERM and the need to remove the ILM</description>
    <arm_group_label>epiretinal membrane group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BCVA &lt; 0,6;&#xD;
&#xD;
        Exclusion Criteria:.&#xD;
&#xD;
          -  secondary ERM, glaucoma, diabetic retinopathy, high myopia, BCVA&gt;0,6&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>82 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel V Lyskin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The S.N. Fyodorov Eye Microsurgery State Institution</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pavel V Lyskin, PhD</last_name>
    <phone>+74994888926</phone>
    <email>plyskin@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irina R Makarenko, MD</last_name>
    <phone>+79032101254</phone>
    <email>makarenkoirina505@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>S.N. Fedorov Nmrc &quot;Mntk &quot;Eye Microsurgery&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>127486</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel V Lyskin, PhD</last_name>
      <phone>+74994888926</phone>
      <email>plyskin@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Irina R Makarenko, MD</last_name>
      <phone>+79032101254</phone>
      <email>makarenkoirina505@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The S.N. Fyodorov Eye Microsurgery State Institution</investigator_affiliation>
    <investigator_full_name>Lyskin Pavel Vladimirovich, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD, ophthalmosurgeon</investigator_title>
  </responsible_party>
  <keyword>epiretinal membrane</keyword>
  <keyword>internal limiting membrane</keyword>
  <keyword>epiretinal fibrosis</keyword>
  <keyword>macular pucker</keyword>
  <keyword>central retina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

